EX VIVO PERFORMANCE STUDY OF LEVOFLOXACIN OCULAR NANOPARTICLES

Polymeric nanoparticles (NPs) of levofloxacin prepared from Eudragit RL 100 and RS 100 have been investigated extensively for ocular delivery. We developed nanoparticles by two techniques viz. 1) solvent displacement method and 2) double emulsion method and characterized for XRD, IR, percent entrapment efficiency, polydispersity, zeta potential, ex vivo transcorneal permeation and stability. The percent transmittance of optimized formulation E1 and A2 was found to be 63.20% and 80.67%, respectively. Particle size of E1 & A2 was found to be 441.70nm and 452.10nm, respectively. The polydispersity was found to be 0.3 and 0.5, respectively. Observed zeta potential values of E1 was +22.00mV and for A2 it was +20.42mV. the values decreased as the concentration of polaxomer increased. The nanoparticles were found to show sustained drug release for more than 7h. The resulting nanoparticles were found to be stable and promising in reducing dose frequency and improving patient compliance for ocular delivery.